Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a US biopharmaceutical company founded in 1988 and headquartered in Tarrytown, New York. Regeneron built its reputation on the VelociSuite technology platform — a suite of proprietary gene targeting and antibody discovery tools that generate fully human monoclonal antibodies with exceptional speed and precision. The company's approved medicines and clinical pipeline reflect deep expertise in ophthalmology, oncology, immunology, cardiovascular disease, and rare genetic diseases.

Regeneron's flagship marketed products include aflibercept (Eylea), which has become the standard of care for wet age-related macular degeneration and diabetic macular edema with multiple active extensions including Eylea HD and PHOTON trial data; dupilumab (Dupixent), a blockbuster IL-4/IL-13 inhibitor approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, COPD, prurigo nodularis, and additional conditions under active investigation; and cemiplimab (Libtayo), a PD-1 inhibitor co-developed with Sanofi with approvals in cutaneous squamous cell carcinoma, basal cell carcinoma, and NSCLC.

Regeneron's oncology strategy combines cemiplimab with bispecific antibodies — including costimulatory bispecifics (CD28 × tumor antigen) designed to amplify T-cell activation specifically within the tumor microenvironment — and with antibody-drug conjugates. The VelociSuite platform also enables rapid generation of antibodies against emerging pathogens (as demonstrated during Ebola and COVID-19), supporting BARDA and NIH-funded infectious disease programs.

Frequently Asked Questions — Regeneron Pharmaceuticals